Most bones grow through the process of endochondral ossification, in which 56 chondrocytes play a central role. Growth cartilage is comprised of chondrocytes arranged in 57 zones that correspond to the stages of an organised program of sequential biological events. 58
A zone of resting chondrocytes blends into a zone of proliferative chondrocytes and then a 59 zone of hypertrophic chondrocytes, which ultimately undergo physiological death. Within 60 the zone of hypertrophy, the cartilage matrix surrounding individual chondrocytes is partially 61 degraded, leaving behind cartilage remnants that form vertical struts onto which bone matrix 62 is deposited by invading osteoblasts (reviewed by Mackie et al., 2011 1 ). The processes of 63 chondrocyte proliferation, differentiation and hypertrophy are tightly regulated by a variety 64 of growth factors, hormones, transcription factors and components of the cartilage matrix. 65
Many of these factors have been characterised, but it is likely that more remain to be 66 identified. The process of physiological death undergone by chondrocytes is less well 67 characterised and there has been a debate in the literature as to whether it occurs through 68 apoptosis or a non-apoptotic mode of death 2; 3 . Moreover, the chondrocytes in growth 69 cartilage express factors capable of regulating the behaviour of cells in the invading 70 ossification front, including vascular endothelial cells, osteoclasts and osteoblasts
. 71
Osteochondrosis is a developmental orthopaedic disorder in which endochondral 72 ossification is disrupted; it affects growing animals of a number of species, including 73 humans 4 . Disregulated endochondral ossification in the articular-epiphyseal growth cartilage 74 results in focal retention of cartilage in subchondral bone, which can lead to cartilage fissures 75 and synovitis. The pathophysiology of osteochondrosis is poorly understood, and possible 76 causes proposed in the literature include ischaemic necrosis of growth cartilage, trauma, 77 altered cartilage extracellular matrix composition and failure of chondrocytes in growth 78 cartilage to undergo hypertrophy [5] [6] [7] [8] [9] . It has been proposed that common mechanisms may 79 occur across species, and there is strong evidence for ischaemic necrosis as the aetiology of 80 . A number of studies in horses have observed an 81 association between the presence of necrotic blood vessels in cartilage canals and 82 osteochondrosis lesions, and experimental surgical transection of blood vessels within 83 cartilage canals causes necrosis of the surrounding cartilage and an associated focal delay in 84 endochondral ossification [10] [11] [12] . It appears, however, that there may be more than one 85 mechanism in horses since many early lesions in this species show no evidence of ischaemic 86 necrosis 4; 10; [13] [14] [15] . The histology of early lesions in humans has not been described. 87
In order to learn about the tissue changes that initiate osteochondrosis, it is important 88 to study early lesions, before the secondary changes associated with clinical disease are 89 observed. A number of recent studies in horses have compared gene or protein expression in 90 the cartilage of early osteochondrosis lesions with that of normal articular cartilage, with the 91 aim of learning more about the pathophysiology of this condition. The studies undertaken so 92 far have focussed on specific molecules known to be involved in chondrocyte function. The 93 distribution of transforming growth factor-β1 and collagen type VI in cartilage is altered in 94 early lesions 14; 16 . Transcripts shown to be more highly expressed in early lesions compared 95 to normal cartilage include collagen types I and X (COL1A1 and COL10A1), matrix 96 metalloproteinases-3 and -13 (MMP3 and MMP13), Runx2 (RUNX2), Indian hedgehog 97 (IHH) and platelet-derived growth factor A (PDGFA) 13; 17 . Since many of these genes are 98 up-regulated with chondrocyte hypertrophy, these observations have led to the conclusion 99 that failure of chondrocytes to undergo hypertrophy is unlikely to be a primary cause of 100 equine osteochondrosis 1; 13 . The aim of the current project was to take an unbiased approach 101 (subtractive hybridization) to identification of genes selectively expressed in early equine 102 osteochondrosis lesions. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
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MATERIALS AND METHODS 107
Tissue samples 108
The use of animal tissues met the requirements of the University of Melbourne 109
Animal Ethics Committee. Articular osteochondrosis lesions were collected (in a previously 110 published study 13 ) from horses (aged 6-11 months) in which osteochondrosis was induced 111 through a high energy diet fed from the age of 4-7 months, following a method that had been 112
shown to induce osteochondrosis 18 . Lesions were identified grossly in osteochondrosis 113 predilection sites as foci of retained cartilage in subchondral bone; none of the lesions 114 showed signs associated with clinical osteochondrosis (such as cartilage fractures or 115 synovitis). Samples of lesions were excised with some underlying bone, and similar samples 116 of normal articular cartilage were obtained from the same joints as the lesions. Samples were 117 divided into two parts. One part was used for RNA extraction from cartilage excised from 118 the specimens, as described 13 . The other part was fixed in 5% gluteraldehyde/4% 119 paraformaldehyde and embedded in Spurr's resin as described 13 , then processed for 120 transmission electron microscopy (TEM) analysis as described 2 . Lesions and control 121 cartilage from three animals were examined. Specimens of normal articular-epiphyseal 122 growth cartilage were harvested from four equine foetuses (estimated gestational age 9-10 123 months) obtained from a local knackery, and processed for TEM as above. 124
Naturally occurring early articular osteochondrosis lesions with some adjacent normal 125 articular cartilage (7 specimens) were collected during a previous study; 6 samples were from 126 the lateral trochlear ridge of the femur of horses aged 4-12 months and 1 from the distal 127 intermediate ridge of the tibia of a 5-month-old horse 14 . In this study, lesions were identified 128 as for the feeding study above, and no specimens from joints showing secondary pathological 129 changes were included. Samples were fixed and embedded in paraffin as described 14 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Subtractive Hybridisation 133
Subtractive hybridisation experiments were carried out using mRNA pooled from 6 134 osteochondrosis lesions (from shoulder joints and articular processes of cervical vertebrae) 135 and from normal articular cartilage collected from 4 horses. Subtractive hybridisation is a 136 labour-intensive method, which cannot feasibly be undertaken on multiple independent 137 samples per group. Samples from different animals and anatomical locations were pooled to 138 increase the chances of identification of genes regulated in all lesions (rather than genes 139 unique to an individual animal or anatomical site). All lesions were considered to be at a 140 similar stage of development since they were induced by feeding the high energy diet. For 141 each lesion, a matching specimen of normal cartilage was obtained from the same joint; we 142 had previously determined that this was the best source of control cartilage for such 143 experiments because there is considerable variability between horses in gene expression in 144 articular cartilage from a specific anatomical site, and considerable variability within 145 individual horses between anatomical sites 13 . The mRNA was purified using magnetic beads 146 coated with oligo dTs and amplified using the MessageAmp™ II aRNA Amplification Kit 147 (Life Technologies, Carlsbad, CA, USA). Subtractive hybridisation was carried out using the 148 PCR Select cDNA Subtraction Kit (Clontech Laboratories Inc., Mountain View, CA, USA). 149
Briefly, the two mRNA populations (lesion and control) were converted to cDNA and 150 digested. One was labelled then the two were hybridised with the unlabelled population in 151 excess. Hybridised sequences were removed. The non-hybridised sequences represented 152 differentially expressed sequences in the labelled population. Two rounds of hybridisation 153 were carried out to identify differentially expressed sequences in the osteochondrosis and the 154 control cDNA. 155
Cloning of subtractive hybridisation products representing candidate differentially 156 expressed genes was carried out using pBluescript II vector and XL-2 Ultracompetent E. coli 
RESULTS
199
Gene expression analysis 200
Subtractive hybridisation experiments were carried out to identify genes that were 201 differentially expressed in cartilage from osteochondrosis lesions compared to normal 202 cartilage. Sixty-six genes were identified as putative differentially expressed genes, either 203 more highly expressed in lesions or more highly expressed in normal cartilage 204 (Supplementary Table 2 ). These included four genes previously found to be differentially 205 expressed in osteochondrosis, i.e. MMP13, RUNX2, COL1A1 and COL10A1, and two 206 previously found not to be differentially expressed, i.e. COL2A1 and VEGFA (not listed in 207   the table) 13 . Thirty-four of the genes have not previously been described in chondrocytes 208 (Supplementary Tables 2, 3) . Quantitative PCR was undertaken in individual lesions isolated from horses that 210 received the high energy diet to determine whether the genes identified in the subtractive 211 hybridisation study were indeed differentially expressed. Results of qPCR experiments 212 confirmed that eight of the genes identified were significantly more highly expressed in 213 lesions compared to normal cartilage ( Figure 1 ); these genes were vacuolar H + ATPase 214
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integrin αV (ITGAV), low density lipoprotein receptor-related protein 4 (LRP4), lumican 216 (LUM), osteopontin (SPP1) and thymosin β4 (TMSB4). These eight genes have not 217 previously been reported to have any involvement in osteochondrosis, and have diverse 218
functions. Some genes were identified by subtractive hybridisation as being putatively more 219 highly expressed in normal cartilage specimens than in osteochondrosis lesions, but the 220 differences were not found to be significant by qPCR. All genes that were not differentially 221 expressed between lesions and normal cartilage were however confirmed as being 222 reproducibly expressed in cartilage samples, with Ct values of less than 40. 223
224
Evidence for the presence of hypertrophic chondrocytes in lesions 225
Some of the differentially expressed genes identified here and in previous studies are 226 known to be up-regulated with chondrocyte hypertrophy 13; 17 . Moreover, we have previously 227 demonstrated in light microscopy studies that the mean area of chondrocytes in sections of 228 experimentally induced lesions is greater than that of chondrocytes in control cartilage 13 , thus 229 TEM studies of lesions were undertaken to determine whether they contained typical 230 hypertrophic chondrocytes. At the time experimentally induced lesions were harvested, the 231 horses were sufficiently old for normal articular-epiphyseal growth cartilage to have been 232 almost completely removed by the invading ossification front, thus the normal cartilage 233 specimens from these horses consisted of articular cartilage containing non-hypertrophic 234 chondrocytes (Figure 2A ) 13 . The chondrocytes in the lesions showed variable morphology, 235 representative lesion. In normal cartilage, chondrocytes showed weak specific staining for 246 ATP6V0D2 ( Figure 3B ). In five of seven lesions examined, however, intense staining was 247 detected in chondrocytes in many regions within the retained cartilage ( Figure 3D ). In the 248 two remaining lesions, only weak staining was observed in the chondrocytes of the retained 249 cartilage. Weak to moderate immunostaining for TMSB4 was detected in normal cartilage; 250 staining was observed both in chondrocytes and in extracellular matrix ( Figure 3C ). Staining 251 of chondrocytes was generally stronger in lesions than in normal cartilage in all seven of the 252 specimens examined with this antibody; the strongest staining in lesions was observed in 253 chondrocytes arranged in clusters ( Figure 3E ). The profiles of cell-associated staining for 254 TMSB4 in lesions were larger than those in normal cartilage, and were suggestive of staining 255 of pericellular matrix within large lacunae ( Figure 3C , E); this was in contrast to staining of 256 ATP6V0D2, which appeared to be restricted to the cytoplasm ( Figure 3D) . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 . In such studies, many of the differences in gene 267 expression are likely to be part of a secondary inflammatory response, rather than associated 268 with the primary change that leads to cartilage retention. In the current study in horses, we 269
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have used an experimental model of osteochondrosis in order to obtain lesions at an early 270 stage. Previous studies in this model as well as in early naturally occurring equine lesions 271 have investigated the association of known cartilage genes and/or proteins with 272 osteochondrosis 13; 14; 16; 17 . In contrast, in the current study, we have taken an unbiased 273 approach to identifying genes that are differentially expressed in early lesions; the subtractive 274 hybridisation method has allowed for the possibility of detecting osteochondrosis-associated 275 genes that were not previously known to be expressed in cartilage. Of the 66 putative 276 differentially expressed genes, four had previously been shown to be more highly expressed 277 in early lesions than in normal cartilage 13 . Since the subtractive hybridisation was 278 undertaken with specimens pooled either from lesions or normal cartilage, qPCR studies were 279 undertaken to determine whether putative differences were statistically significant. Through 280 this process, eight genes not previously identified as early osteochondrosis-associated genes 281 were confirmed as being more highly expressed in lesions than in normal cartilage, including 282 one gene that had not previously been identified in cartilage, i.e. ATP6V0D2. The 283 differentially expressed genes cover a variety of functions, but the majority encode 284 extracellular matrix proteins or proteins with known or putative functions in extracellular 285 matrix turnover or interactions with cells. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Three of the genes found to be more highly expressed in the osteochondrosis lesions 287 than in controls encode extracellular matrix proteins in bone and/or cartilage. Lumican is a 288 small proteoglycan known to be expressed in articular cartilage; the level of expression in 289 this location in humans is higher in adults than in infants 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 . Sclerostin is also expressed by hypertrophic chondrocytes and inhibits IL-332 1α-stimulated aggrecan degradation in cartilage explants 33; 34 . It is possible that the enhanced 333 expression of LRP4 in osteochondrosis lesions (observed in the current study) contributes to 334 the retention of cartilage in subchondral bone both through increased expression of cartilage 335 matrix and inhibition of matrix degradation. Such roles for LRP4 may help to explain how 336 cartilage is retained in subchondral bone despite the concurrently elevated levels of matrix-337 degrading enzymes such as cathepsin K and MMP-13. 338 Other genes that were identified by subtractive hybridisation but were not confirmed 355 as being differentially expressed in osteochondrosis lesions by qPCR included 34 genes that 356 have not been described as being expressed in cartilage (Supplementary Table 3 ). Many of 357 these are genes encoding proteins with known functions in transcription as well as protein 358 translation and secretion, which is in keeping with the high secretory activity of 359 chondrocytes. Further investigations will be needed to clarify specific roles of the novel 360 genes in regulation of chondrocyte behaviour and/or cartilage function. 361 A limitation of the study was that insufficient material was available from some of the 362 horses used in the experimental osteochondrosis study (on which the current study was 363 based) to undertake qPCR for all of the 66 putative differentially expressed genes. It is 364 future studies on the pathogenesis of osteochondrosis at that site should be 'focused on foals 369 younger than 4.5 months old'. This recommendation was based on the conclusion that the 370 lesions are caused by necrosis of cartilage canal blood vessels, and the fact that such vessels 371 are absent after 4.5 months. As noted in the introduction, while there is strong evidence that 372 many equine osteochondrosis lesions are caused by necrosis related to failure of cartilage 373 canal blood vessels, in some studies lesions have been described in which no such association 374 has been observed. Since there is a possibility that some lesions are caused by a different 375 mechanism, it is appropriate to investigate lesions from sites related to growth plates that are 376 still active, with the proviso that no gross signs of secondary changes are present. This is the 377 approach taken for the specimens used in the immunohistochemical studies presented here; 378 the specimens (distal ends of femur and tibia) were taken several months before the expected 379 closure of the associated growth plates 37 . The specimens from the feeding trial were from 380 sites (glenoid of the scapula and cervical vertebrae) for which specific growth plate closure 381 data are not available, however these bones continue to grow significantly in the second year 382 of life 38 . Horses reach full skeletal maturity in the third year of life. 383
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ANKRA2 GCTGCTTGACTGTGGAGTTG TTGGGTCAGCTCCATTTTCT ANXA1 TAAGGGTGACCGATCTGAGG TTCTCCTTTCTCCTGCTTCG ATP6V0D2 AGAGTGGCTGAGCACTACGG CACATCCTCCAAGGTCTTTCC BAK1 GGCCCTGCATGTCTACCAG GCCATTTCCCAAGTCCAGAG BCL2 TGGATGACCGAGTACCTGAAC CCTTCAGAGACAGCCAGGAG CALM1 GCACCATTGACTTCCCaGAA GTAGTTCTGCCGCACTGATG CDK11A CATACAACAACCTCCGCAAA CTTGAGACCGTCCTCTGCAT CHTOP TCTGTCCAGGCAGCATTAAA GGGCAAGCCTCTCTGGATTA CLIC1 ACTCTGGCTGACTGCAACCT GAACTCTTCCCGAGCATAGG CTSK AAGCCTGACCTCCTTCCAGT CCGCATGGTTCAGATTATCA CYTB CCGGAAATCTCACCCACTAA GAGGGAGCCGAAGTTTCATC DDX5 CGACCTTATCTCTGTGCTTCG AATATCTGTCCCGACGGTCA EEF1G AACGAGTTACGCTGGCTGAC GCTGGTTAATGCAGGTGAGG FBN1 AGGAAACGGAGAAGCACAAA AACATGGCGGTCTTCTCAAC FOXA3 CTGGCCGAGTGGAGCTACTA CAGAGGGTTCAGGGTCATGT FTL ATCAAGAAGATGGGCGACAA CTTGAGGGTGAGCCTTTCAA GJA1 GTCACTTGGCGAGCGTACTT GCAGGATTCGGAAAATGAAA GNB1 GGGATAACCTCCGTGTCCTT AGGCAGCTGACACGGTTG GOLF3 GCCTCCAGAGACTGTCCAGA CCCTTTTCCACCAGGTTTTT HIVEP2 TTGTCCATGGGGCAGTATTT TGGAGCCTGGATGTTCATAA HSP70 ATCGAGCGCATGGTTCTG ATCTTGCCCTTCAAGCCTTC IBSP GCCACAATATTCTCTTTACAAGCA CCATCTCCATTTTCTTCAGAGG ITGAV GCAGTTCTAGCAGGGTTGTTG CCATTTTCATGAGGTTGAAGC KCTD10 GAAGCAACAACAAATACTCATATACCA TGAAGCGCAGAGACAGCTTA KDELR2 TCACAACTCGTTACCTGGATCTT ACACTGTGGCATAGGAGCAG LDHA AATCTTAGGCGAGTGCATCC ACGGCACACTAAGGAAGACG LECT1 CAGAGCATCTCCTCCGAACT CAAGAAGCTGTTGTCCTTCACA LRP4 ATTGAAGCAATCCCAACACC AGGTCATCCCACTCAGCATC LUM CCTCTCTGCTTGAGCTGGAT GAGGTCCCAGGATCTTACAGAA MFAP2 TTCCAGTTCCAGTCTCAGCA CTCCGTCTCTGCATTTCCTG MFN1 CAACACAATGCAAAGCTCCT CACTGCTTGAATGTAGAAACTGC MRRF ACGGAAGGTTCGTACCAATG ACCTGTCCAGCTCTGCAACT MT-ND2 TCCCACACATGAAACAAAACA GGGAGGATGATGCTGCTATT NACA GCAGCTGCTGAGAAATTCAA ACTTCCACACCCGTTTCATC NHLRC3 TCATGGTATATTTGCAGCCAGT TGGGGTACCCAAGACTTGAA NUDT16 GGACCCAGGGCTGCTCTT GTCCTGCCTGTTCACCAA OGN CACCATTAACCCCCAAGAAA GGACAGCATCAATGTCCACTT PIP4K2A GCCAAAGAACTGCCAACTTT TGAGCTTTAACTGGGCAAGAA PLOD2 GCACCCGTTACACTGAAGGT CGTAGAAGCGTCGTGATGAG PP1CB TGGCGAGTTTGATAATGCTG TTAGCTGTCCGAGGTGGAGT PSAP GTGGAAATCCTGGTGGAGGT AAAGAGGCTTATGGGCTGTG PTAR1 GGCATATTTTCTACCTTCAGCA GGGAATAGCCTTGCTTGCTA PURB AcGTGGGgTGCAACAAgTAt ATCCGCATACCGaCAAAAaG
